HC Wainwright Comments on Evotec's Q3 Earnings (NASDAQ:EVO)

Key Points

• HC Wainwright has revised Evotec's Q3 2025 earnings estimate to ($0.05) per share, down from a prior estimate of ($0.04), while maintaining a "Buy" rating with a target price of $7.00.
• Current consensus estimates for Evotec's full-year earnings are expected to be ($0.41) per share, with forecasts showing improvements in subsequent years.
• Recent trading data shows Evotec shares opened at $3.76, with notable institutional investments increasing ownership in the company.

Evotec AG (NASDAQ:EVO - Free Report) - Equities researchers at HC Wainwright reduced their Q3 2025 earnings per share estimates for Evotec in a research note issued on Thursday, August 14th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($0.05) per share for the quarter, down from their prior forecast of ($0.04). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Evotec's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Evotec's Q4 2025 earnings at $0.22 EPS, FY2025 earnings at ($0.09) EPS, Q1 2026 earnings at ($0.02) EPS, Q2 2026 earnings at ($0.02) EPS, Q4 2026 earnings at $0.02 EPS, FY2026 earnings at ($0.01) EPS, FY2027 earnings at $0.30 EPS, FY2028 earnings at $0.39 EPS and FY2029 earnings at $0.53 EPS.

A number of other brokerages have also issued reports on EVO. Deutsche Bank Aktiengesellschaft raised Evotec from a "sell" rating to a "hold" rating in a research report on Thursday, April 24th. Royal Bank Of Canada reissued an "outperform" rating on shares of Evotec in a research report on Thursday, May 15th.

Evotec Price Performance

Shares of Evotec stock opened at $3.76 on Monday. The stock's fifty day moving average is $4.06 and its 200-day moving average is $3.97. The company has a quick ratio of 1.49, a current ratio of 1.58 and a debt-to-equity ratio of 0.42. Evotec has a 12-month low of $2.84 and a 12-month high of $5.64.

Hedge Funds Weigh In On Evotec

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new position in Evotec in the 4th quarter valued at approximately $27,000. Valeo Financial Advisors LLC acquired a new position in Evotec in the 2nd quarter valued at approximately $43,000. CSS LLC IL acquired a new position in shares of Evotec in the 4th quarter worth approximately $50,000. Bank of America Corp DE raised its holdings in shares of Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after buying an additional 9,289 shares in the last quarter. Finally, UMB Bank n.a. acquired a new position in shares of Evotec in the 2nd quarter worth approximately $56,000. Institutional investors and hedge funds own 5.81% of the company's stock.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.